FI880017A - Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu - Google Patents

Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu Download PDF

Info

Publication number
FI880017A
FI880017A FI880017A FI880017A FI880017A FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A FI 880017 A FI880017 A FI 880017A
Authority
FI
Finland
Prior art keywords
variants
preparation
trypsin inhibitor
pancreatic secretory
secretory trypsin
Prior art date
Application number
FI880017A
Other languages
English (en)
Swedish (sv)
Other versions
FI97139B (fi
FI97139C (fi
FI880017A0 (fi
Inventor
John Collins
Helmut Bloecker
Ronald Frank
Friedhelm Maywald
Hans Fritz
Wolfgang Bruns
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI880017A0 publication Critical patent/FI880017A0/fi
Publication of FI880017A publication Critical patent/FI880017A/fi
Publication of FI97139B publication Critical patent/FI97139B/fi
Application granted granted Critical
Publication of FI97139C publication Critical patent/FI97139C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/26Containing cys-cys disulfide bridge between nonadjacent cysteine residues
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/27Cyclic peptide or cyclic protein
FI880017A 1987-01-07 1988-01-05 Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu FI97139C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8700204 1987-01-07
GB08700204A GB2199582A (en) 1987-01-07 1987-01-07 Analogues of pancreatic secretory trypsin inhibitor

Publications (4)

Publication Number Publication Date
FI880017A0 FI880017A0 (fi) 1988-01-05
FI880017A true FI880017A (fi) 1988-07-08
FI97139B FI97139B (fi) 1996-07-15
FI97139C FI97139C (fi) 1996-10-25

Family

ID=10610323

Family Applications (1)

Application Number Title Priority Date Filing Date
FI880017A FI97139C (fi) 1987-01-07 1988-01-05 Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu

Country Status (15)

Country Link
US (1) US5126322A (fi)
EP (1) EP0278112B1 (fi)
JP (2) JPS63169994A (fi)
KR (1) KR960010949B1 (fi)
CN (1) CN1030999C (fi)
AT (1) ATE97421T1 (fi)
AU (1) AU592486B2 (fi)
DE (1) DE3788216D1 (fi)
DK (1) DK3688A (fi)
ES (1) ES2059356T3 (fi)
FI (1) FI97139C (fi)
GB (1) GB2199582A (fi)
HU (1) HUT46068A (fi)
IL (1) IL85020A (fi)
ZA (1) ZA8860B (fi)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8894994B2 (en) 2010-05-24 2014-11-25 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10548955B2 (en) 2015-02-23 2020-02-04 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8172787A (en) * 1986-10-30 1988-05-25 Synergen Biologicals, Inc. Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
JPS6427473A (en) * 1987-07-23 1989-01-30 Mochida Pharm Co Ltd Human pancreas-secreting trypsin inhibitor and production thereof
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
ES2063161T3 (es) * 1988-03-07 1995-01-01 Ciba Geigy Ag Proteinas modificadas.
US5180667A (en) * 1988-03-07 1993-01-19 Ciba-Geigy Corporation Genes encoding eglin C mutants
JPH07102137B2 (ja) * 1988-07-19 1995-11-08 塩野義製薬株式会社 修飾ヒトpsti
DE3907492A1 (de) * 1989-03-08 1990-09-13 Biotechnolog Forschung Gmbh Verfahren zur isolierung und reinigung von hpsti und hpsti-varianten
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
EP0699750A1 (en) * 1994-06-07 1996-03-06 Gesellschaft für biotechnologische Forschung mbH (GBF) A collection of phagemids, a collection of Escherichia coli cells carrying the phagemids, a collection of phagemid particles produced from said collection and phagemid particles obtained according to the process
JPH09124698A (ja) 1995-10-27 1997-05-13 Sagami Chem Res Center ヒトpec−60様蛋白質およびそれをコードするdna
US6703201B1 (en) 1995-10-27 2004-03-09 Sagami Chemical Research Center Human PEC-60-like protein and DNA encoding this protein
US5851987A (en) * 1997-04-14 1998-12-22 Incyte Pharmaceuticals, Inc. Human tumor-associated Kazal inhibitor-like polypeptides and encoding polynucleotides
WO2008052238A1 (en) * 2006-11-01 2008-05-08 The University Of Sydney Treatment of urological cancer
ES2753183T3 (es) 2007-02-12 2020-04-07 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2701890C2 (de) * 1977-01-19 1983-08-04 Hoechst Ag, 6230 Frankfurt Peptielischer Glycosidhydrolase-Inhibitor aus einem Streptomyceten und seine Verwendung
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
IL77227A (en) * 1984-12-06 1992-08-18 Synergen Biolog Inc Recombinant methods for production of serine protease inhibitors and methods for isolation of same
US4760130A (en) * 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトpstiの製造法
KR960013466B1 (ko) * 1986-10-14 1996-10-05 시오노기 세이야꾸 가부시끼가이샤 단백질의 신규제법
AU8172787A (en) * 1986-10-30 1988-05-25 Synergen Biologicals, Inc. Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8894994B2 (en) 2010-05-24 2014-11-25 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9034602B2 (en) 2010-05-24 2015-05-19 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US11214787B2 (en) 2010-05-24 2022-01-04 Synthetic Biologies, Inc. Modified beta-lactamases and methods and uses related thereto
US9301995B2 (en) 2010-05-24 2016-04-05 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9301996B2 (en) 2010-05-24 2016-04-05 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US10253306B2 (en) 2010-05-24 2019-04-09 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US10041056B2 (en) 2010-05-24 2018-08-07 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9765320B2 (en) 2010-05-24 2017-09-19 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9587234B2 (en) 2010-05-24 2017-03-07 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
US9695409B2 (en) 2014-04-17 2017-07-04 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
US9464280B1 (en) 2014-04-17 2016-10-11 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9783797B1 (en) 2014-04-17 2017-10-10 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10011824B2 (en) 2014-04-17 2018-07-03 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US9404103B1 (en) 2014-04-17 2016-08-02 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11608494B2 (en) 2014-04-17 2023-03-21 Theriva Biologics, Inc. Beta-lactamases with improved properties for therapy
US10087433B1 (en) 2014-04-17 2018-10-02 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11236319B2 (en) 2014-04-17 2022-02-01 Synthetic Biologies, Inc. Beta-lactamases with improved properties for therapy
US9376673B1 (en) 2014-04-17 2016-06-28 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10336995B2 (en) 2014-04-17 2019-07-02 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10767171B2 (en) 2014-04-17 2020-09-08 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US10584326B2 (en) 2014-04-17 2020-03-10 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
US11542510B2 (en) 2014-08-28 2023-01-03 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
US10828260B2 (en) 2014-10-08 2020-11-10 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10792346B2 (en) 2014-12-23 2020-10-06 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11596674B2 (en) 2014-12-23 2023-03-07 Synthetic Biologies, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US10046035B2 (en) 2014-12-23 2018-08-14 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11944669B2 (en) 2014-12-23 2024-04-02 Theriva Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US11123413B2 (en) 2015-02-23 2021-09-21 Synthetic Biologies, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10548955B2 (en) 2015-02-23 2020-02-04 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11253577B2 (en) 2015-03-06 2022-02-22 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11872268B2 (en) 2015-03-06 2024-01-16 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection

Also Published As

Publication number Publication date
DE3788216D1 (de) 1993-12-23
KR880009125A (ko) 1988-09-14
EP0278112A3 (en) 1990-01-10
FI97139B (fi) 1996-07-15
GB8700204D0 (en) 1987-02-11
AU592486B2 (en) 1990-01-11
KR960010949B1 (ko) 1996-08-14
US5126322A (en) 1992-06-30
GB2199582A (en) 1988-07-13
EP0278112A2 (de) 1988-08-17
ATE97421T1 (de) 1993-12-15
ZA8860B (en) 1988-10-26
JPH10117786A (ja) 1998-05-12
FI97139C (fi) 1996-10-25
CN1030999C (zh) 1996-02-14
ES2059356T3 (es) 1994-11-16
DK3688D0 (da) 1988-01-06
JPS63169994A (ja) 1988-07-13
FI880017A0 (fi) 1988-01-05
AU1003888A (en) 1988-09-01
HUT46068A (en) 1988-09-28
CN88100146A (zh) 1988-08-31
DK3688A (da) 1988-07-08
IL85020A (en) 1993-02-21
IL85020A0 (en) 1988-06-30
EP0278112B1 (de) 1993-11-18

Similar Documents

Publication Publication Date Title
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
ATE81673T1 (de) Verfahren zur beseitigung von nendaminos|ureresten aus eukaryotpolypeptidanlagen und so erzeugte polypeptide.
ATE90944T1 (de) Fuer ein hirudinaehnliches protein kodierende dns- sequenz und verfahren zur herstellung eines solchen proteins.
DE68919246T2 (de) Verfahren zur Herstellung von Aminosäuren.
HUT68021A (en) Improved activating process of recombinant proteins
SE8801701D0 (sv) Production technology based on enzymic method
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
DE3688324D1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
AU5232886A (en) Serine protease inhibitors and methods for isolation of same
HU9201723D0 (en) Process for the production of herpes protheae, of preparations containing them and the use of the enzym
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
DE59108128D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten
FI830813L (fi) Foerfarande foer omvandling av pre-proinsulinanaloger till insulin
DK0467839T3 (da) In-vitro-behandling af fusionsproteiner
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
ATE103341T1 (de) Antikoerper gegen hochkonservierte aminosaeuresequenzen von immunogenen substanzen, verfahren zur herstellung dieser antikoerper, sowie deren verwendung in immunoassays.

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: GESELLSCHAFT FUER BIOTECHNOLOGISCHE

MM Patent lapsed

Owner name: GESELLSCHAFT FUER BIOTECHNOLOGISCHE FORSCHUNG MBH